Induction of phenotype modifying cytokines by FERMT1 mutations

Area of Science:

• Dermatology
• Molecular Biology
• Genetics

Background:

• Kindler syndrome (KS) is a rare, progressive skin disorder caused by mutations in the FERMT1 gene, leading to diminished cell adhesion and early mechanobullous disease.
• The underlying mechanisms for later KS features, including poikiloderma and mucocutaneous fibrosis, are not fully understood.
• Kindlin-1, the FERMT1 gene product, is crucial for integrin activation in epithelial cells, but its role in dermal connective tissue pathology was unclear.

Purpose of the Study:

• To elucidate the mechanisms by which loss of intracellular kindlin-1 in epidermal keratinocytes contributes to the dermal pathology observed in Kindler syndrome.
• To investigate the paracrine signaling pathways initiated by stressed, kindlin-1-deficient keratinocytes that affect dermal fibroblasts.

Main Methods:

• Analysis of kindlin-1-deficient keratinocytes and their response to cellular stress.
• Assessment of cytokine expression profiles in stressed keratinocytes.
• Investigation of downstream effects in the dermis, including inflammatory cell presence, fibroblast activation, and extracellular matrix deposition.

Main Results:

• Kindlin-1-deficient keratinocytes exhibit upregulated expression of pro-inflammatory and profibrotic cytokines (e.g., IL-20, IL-24, TGF-β2, PDGFB, CTGF) upon cellular stress.
• These secreted cytokines induce a paracrine inflammatory response in the dermis, characterized by the presence of TGF-β, IL-6, and CTGF.
• The dermal inflammatory milieu promotes fibroblast activation and differentiation into myofibroblasts, leading to excessive extracellular matrix deposition.

Conclusions:

• Epidermal kindlin-1 deficiency initiates a cascade involving keratinocyte stress, cytokine signaling, dermal inflammation, and fibroblast activation.
• This pathway provides a mechanistic link between epithelial defects and the development of progressive dermal fibrosis in Kindler syndrome.
• Targeting these paracrine signaling pathways may offer therapeutic strategies for managing the fibrotic complications of Kindler syndrome.